Prothena (PRTA) Competitors $6.81 -0.06 (-0.87%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$6.80 0.00 (-0.07%) As of 08/1/2025 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRTA vs. ABCL, HROW, WVE, NTLA, PHVS, CVAC, CDTX, PAHC, CALT, and AUPHShould you be buying Prothena stock or one of its competitors? The main competitors of Prothena include AbCellera Biologics (ABCL), Harrow (HROW), WAVE Life Sciences (WVE), Intellia Therapeutics (NTLA), Pharvaris (PHVS), CureVac (CVAC), Cidara Therapeutics (CDTX), Phibro Animal Health (PAHC), Calliditas Therapeutics AB (publ) (CALT), and Aurinia Pharmaceuticals (AUPH). These companies are all part of the "pharmaceutical products" industry. Prothena vs. Its Competitors AbCellera Biologics Harrow WAVE Life Sciences Intellia Therapeutics Pharvaris CureVac Cidara Therapeutics Phibro Animal Health Calliditas Therapeutics AB (publ) Aurinia Pharmaceuticals AbCellera Biologics (NASDAQ:ABCL) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations. Does the media refer more to ABCL or PRTA? In the previous week, AbCellera Biologics had 1 more articles in the media than Prothena. MarketBeat recorded 5 mentions for AbCellera Biologics and 4 mentions for Prothena. AbCellera Biologics' average media sentiment score of 0.53 beat Prothena's score of 0.16 indicating that AbCellera Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbCellera Biologics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prothena 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer ABCL or PRTA? AbCellera Biologics currently has a consensus target price of $8.75, suggesting a potential upside of 106.37%. Prothena has a consensus target price of $31.50, suggesting a potential upside of 362.56%. Given Prothena's higher probable upside, analysts plainly believe Prothena is more favorable than AbCellera Biologics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AbCellera Biologics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00Prothena 1 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.33 Do institutionals & insiders believe in ABCL or PRTA? 61.4% of AbCellera Biologics shares are held by institutional investors. Comparatively, 97.1% of Prothena shares are held by institutional investors. 28.9% of AbCellera Biologics shares are held by insiders. Comparatively, 9.2% of Prothena shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has stronger earnings and valuation, ABCL or PRTA? Prothena has higher revenue and earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbCellera Biologics$28.83M43.89-$162.86M-$0.56-7.57Prothena$137.94M2.66-$122.31M-$2.08-3.27 Is ABCL or PRTA more profitable? Prothena has a net margin of -79.94% compared to AbCellera Biologics' net margin of -737.56%. AbCellera Biologics' return on equity of -15.98% beat Prothena's return on equity.Company Net Margins Return on Equity Return on Assets AbCellera Biologics-737.56% -15.98% -12.38% Prothena -79.94%-21.61%-19.32% Which has more volatility & risk, ABCL or PRTA? AbCellera Biologics has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500. Comparatively, Prothena has a beta of -0.03, suggesting that its stock price is 103% less volatile than the S&P 500. SummaryAbCellera Biologics beats Prothena on 10 of the 16 factors compared between the two stocks. Get Prothena News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRTA vs. The Competition Export to ExcelMetricProthenaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$366.56M$3.00B$5.48B$9.51BDividend YieldN/A2.43%4.73%4.08%P/E Ratio-3.2717.6228.6723.80Price / Sales2.66179.18373.9066.65Price / CashN/A41.9535.4557.96Price / Book0.758.508.275.55Net Income-$122.31M-$55.06M$3.24B$259.03M7 Day Performance1.95%-3.98%-3.69%-4.59%1 Month Performance7.75%9.59%4.33%4.46%1 Year Performance-67.80%6.72%25.95%18.03% Prothena Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRTAProthena3.1085 of 5 stars$6.81-0.9%$31.50+362.6%-69.5%$366.56M$137.94M-3.27130News CoverageUpcoming EarningsABCLAbCellera Biologics2.4067 of 5 stars$5.15+15.0%$8.75+69.9%+39.0%$1.34B$28.83M-9.20500News CoverageUpcoming EarningsHigh Trading VolumeHROWHarrow2.5207 of 5 stars$37.08+3.3%$63.83+72.2%+27.2%$1.32B$199.61M-66.21180Gap DownWVEWAVE Life Sciences4.7497 of 5 stars$7.87-5.6%$20.15+156.1%+40.1%$1.30B$108.30M-9.37240News CoverageEarnings ReportAnalyst ForecastNTLAIntellia Therapeutics4.501 of 5 stars$12.63+4.7%$33.37+164.2%-54.3%$1.25B$57.88M-2.41600News CoverageUpcoming EarningsGap DownHigh Trading VolumePHVSPharvaris1.706 of 5 stars$23.84+2.5%$36.20+51.8%+25.5%$1.22BN/A-7.9230CVACCureVac3.5998 of 5 stars$5.40+0.2%$6.83+26.5%+51.1%$1.21B$579.18M5.87880News CoverageCDTXCidara Therapeutics3.1487 of 5 stars$57.05-4.9%$57.29+0.4%+389.1%$1.21B$1.27M-1.9490Upcoming EarningsHigh Trading VolumePAHCPhibro Animal Health4.1332 of 5 stars$29.14-0.9%$24.40-16.3%+41.1%$1.19B$1.19B37.361,940Positive NewsDividend AnnouncementCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180AUPHAurinia Pharmaceuticals2.3298 of 5 stars$8.62-0.1%$11.50+33.4%+87.0%$1.17B$235.13M30.79300Trending NewsEarnings ReportAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies AbCellera Biologics Competitors Harrow Competitors WAVE Life Sciences Competitors Intellia Therapeutics Competitors Pharvaris Competitors CureVac Competitors Cidara Therapeutics Competitors Phibro Animal Health Competitors Calliditas Therapeutics AB (publ) Competitors Aurinia Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRTA) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prothena Corporation plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Prothena With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
